Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Astex Climbs on Expected European Approval: San Francisco Mover

Don't Miss Out —
Follow us on:

Aug. 21 (Bloomberg) -- Astex Pharmaceuticals Inc. rose the most in almost seven months on expectations that the developer of experimental cancer drugs will receive regulatory approval this quarter from Europe for its leukemia treatment.

Astex surged 15.4 percent to $2.77 at the close in New York, the most since Jan. 27. The shares of the Dublin, California-based company have risen 47 percent this year.

“They’ve had a good run, really a great run since the middle of May,” George Zavoico, an analyst with McNicoll Lewis & Vlak LLC in New York, said in an interview. He has a buy rating on Astex, with a target price of $3.50.

Last month, Astex said Janssen-Cilag International NV, which licenses its treatment outside the U.S., Canada and Mexico, was notified that the Committee for Medical Products for Human Use of the European Medicines Agency backed recommending approval. The drug, called Dacogen for Injection, is used to treat older adults suffering from acute myeloid leukemia.

The final regulatory decision is expected in the end of the third quarter, Astex said in a statement July 20. If approved, Dacogen would receive 10 years of market exclusivity in the European Union and Astex would earn “a milestone payment” of $5 million, the company said in an earnings statement July 30.

Astex also reported Dacogen second-quarter royalty revenue increased 25 percent to $14.4 million from $11.5 million a year earlier.

“Since their pipeline is still early stage, investors tend to focus on Dacogen royalties, and they did have a good quarter,” Zavoico said.

The stock gain “is a combination of continued strength in Dacogen sales, royalty revenue rising in second-quarter year over year even though it was down from the first quarter as expected due to the annual rest, and anticipated approval from the EU this quarter,” he said.

To contact the reporters responsible for this story: Samantha Zee in San Francisco at szee@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.